Transrectal Ultrasound Market is Segmented By Type (Cart/Trolley based, Portable), By Application(Diagnostic, Benign Prostatic Hyperplasia, Others, Image-guided treatment), By End-User (Hospitals, Diagnostic Laboratories, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Transrectal Ultrasound Market Overview
Transrectal Ultrasound Market is Predicted to reach at a CAGR of 4.4% during the forecast period (2023-2030). TRUS, or transrectal ultrasonography, is a method of creating an image of organs in the pelvis that is most commonly used to perform an ultrasound-guided needle biopsy evaluation of the prostate gland in men who have elevated prostate-specific antigen or prostatic nodules on digital rectal exam. Prostate cancer, benign prostatic hypertrophy, or prostatitis can all be detected with a TRUS-guided biopsy. TRUS can also be used to stage primary rectal cancer and detect other diseases of the lower rectum.
Transrectal Ultrasound Market Summary and Scope
|
Metrics |
Details |
|
Market CAGR |
4.4% |
|
Segments Covered |
By Type, By Application, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Transrectal Ultrasound Market Dynamics and Trends
The increased frequency of urological diseases and the rise in the number of prostate cancer cases globally will fuel the growth of the transrectal ultrasound market. The growing senior population and the prevalence of various chronic and acute diseases are driving the growth of the transrectal ultrasound market. Furthermore, the introduction of technological advancements in the medical sector, such as real-time monitoring, artificial intelligence, and others, provides the market impetus, along with people's increasing disposable incomes and willingness to spend on minimally invasive surgeries, will likely help the market gain traction in the coming years.
The increase in prevalance of urological abnormalities in the market will drive the market growth
Demand for effective treatment for urological abnormalities such as prostate cancer is increasing, owing primarily to rapid changes in lifestyle," "This is one of the primary factors driving the TRUS market." Transrectal ultrasound of the prostate aids in the detection of cysts in the male reproductive system and determining whether they are cancerous or not. This is why males prefer transrectal ultrasound scans to other standard tests. Both developed and developing countries have sophisticated and well-equipped healthcare infrastructure. The TRUS market is being propelled forward by this and increased product availability.
The TRUS industry is expected to develop due to several different variables. Governments worldwide are working together to ensure the early identification and treatment of prostate cancer. In combination with technical advancements, this feature is expected to boost the TRUS market.
To obtain reliable and exact test findings, transrectal ultrasonography or endorectal ultrasound employs various technologies. 2D, 3D, and other technologies, such as real-time imaging, are among them. The introduction of such technologies is expected to propel the TRUS market further in the future years. TRUS devices are projected to become more widely used in hospitals, clinics, diagnostic centers, and surgical facilities. It will encourage companies to use emerging technologies to introduce new TRUS devices.This contributes to the growth of the global transrectal ultrasound market.
Stringent Healthcare Policies by Regulatory Authorities is likely to hamper the market growth
Despite the market's great development prospects, various obstacles may limit its expansion in the next years. Strict restrictions governing the approval of healthcare drugs and diagnoses may stifle market expansion. Furthermore, product recalls due to safety concerns may limit the TRUS market's growth in the upcoming years. Nonetheless, several businesses intend to engage in R&D and technological advancements to help the TRUS market flourish.
COVID-19 Impact Analysis on Transrectal Ultrasound Market
Manufacturers swiftly adjust their company practices and purchasing techniques to satisfy market demand as the COVID-19 problem worsens. Because the virus has spread over the globe, individuals are focusing more on their health and building immunity. Transrectal ultrasound is a preventative measure for detecting prostate cancer early, and it will be in high demand during the predicted period. However, because it is not a life-or-death screening, it may take a backseat as the medical community deals with COVID-related emergencies.
Transrectal Ultrasound Market Segmentation Analysis
The prostate cancer segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)
Over the projection period, the prostate cancer segment is expected to grow significatly, owing to rising number of operations, rising number of prostate cancer cases, and rising geriatic population. For instance, except for skin cancer, prostate cancer is the most common cancer in men. An estimated 248,530 men in the United States are diagnosed with prostate cancer in 2021. According to the Cancer.org , Prostate cancer affects about 1 in every 8 men at some point in their lives. Older males and non-Hispanic Black men are more prone to acquire prostate cancer. Men over the age of 65 account for about 6 out of every 10 occurrences, whereas men under 40 are extremely rare. Men are diagnosed at an average age of 66.
Furthermore, several reimbursements and medical policies for prostate cancer treatments in various developing and developed regions are also driving the growth of the prostate cancer segment during the forecast period.
Transrectal Ultrasound Market Geographical Share
North America region holds the largest market share of global transrectal ultrasound market
Due to significant favorable adoption of technologically advanced software modalities, reimbursement policies and increased government initiatives to raise patient awareness for early diagnosis, the United States is likely to account for a dominant share of the global urology ultrasound market.
The Asia Pacific transrectal ultrasound market is estimated to rise at the fastest growth rate by 2028 due to rising healthcare expenditures, improved infrastructure due to rising healthcare investments, an increased number of patients with urological disorders, among other factors. Because of the high patient preference for ultrasounds as a primary imaging modality in China and India, major players have expanded their operations in these countries through strategic distribution agreements with local distributors with a significant regional presence.
Transrectal Ultrasound Companies and Competitive Landscape
The transrectal ultrasound market is highly competitive with presence of several major companies contributing to the growth of the market including GE Healthcare, BK Medical Holding Company, Inc., KOELIS, Exact Imaging, TELEMED, Shenzhen Mindray Bio Medical Electronics, among others.
Some of the major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance in 2018, Trinity, a fully integrated platform, 3D-image-based cartographer designed specifically for personalized prostate care, was created by KOELIS.
Also, in May 2017, at the American Urological Association (AUC) in Boston, Analogic Corporation launched the bK Fusion, an MRI-US fusion biopsy platform.
Exact Imaging
Overview: Micro-ultrasound systems for urological applications are being developed. In addition to performing systematic TRUS biopsies for prostate cancer imaging, the company's systems provide resolution for visualization and targeting of suspicious regions, allowing urologists to perform targeted biopsies within a standard urological workflow.
Product Portfolio:
ExactVu: As a new tool for urologists to perform targeted biopsies within a standard urological workflow, the ExactVu micro-ultrasound platform provides the most practical solution. Exact Imaging created the ExactVuTM system, the first micro-ultrasound system that operates at 29 MHz and provides unrivaled resolution.
